97 related articles for article (PubMed ID: 16600668)
1. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy.
Yu Q
Drug Resist Updat; 2006; 9(1-2):19-25. PubMed ID: 16600668
[TBL] [Abstract][Full Text] [Related]
2. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
Bossi G; Sacchi A
Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
[TBL] [Abstract][Full Text] [Related]
3. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
6. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
7. MDM2 inhibitors for cancer therapy.
Vassilev LT
Trends Mol Med; 2007 Jan; 13(1):23-31. PubMed ID: 17126603
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
9. Strategies for manipulating the p53 pathway in the treatment of human cancer.
Hupp TR; Lane DP; Ball KL
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
[TBL] [Abstract][Full Text] [Related]
10. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
11. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
12. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
13. The genetics of the p53 pathway, apoptosis and cancer therapy.
Vazquez A; Bond EE; Levine AJ; Bond GL
Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
[TBL] [Abstract][Full Text] [Related]
14. Classic and novel roles of p53: prospects for anticancer therapy.
Fuster JJ; Sanz-González SM; Moll UM; Andrés V
Trends Mol Med; 2007 May; 13(5):192-9. PubMed ID: 17383232
[TBL] [Abstract][Full Text] [Related]
15. A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop.
Xiong L; Kou F; Yang Y; Wu J
J Cell Biol; 2007 Sep; 178(6):995-1007. PubMed ID: 17846171
[TBL] [Abstract][Full Text] [Related]
16. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
19. Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.
Martinez JD
Future Oncol; 2010 Dec; 6(12):1857-62. PubMed ID: 21142860
[TBL] [Abstract][Full Text] [Related]
20. Activation of p53 by specific agents in potential cancer therapy.
Ho JW; Song JZ; Leung YK
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):131-5. PubMed ID: 15777220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]